Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary small vessel disease caused by NOTCH3 mutations affecting vascular smooth muscle cells (VSMCs) in cerebral arteries and arterioles. VSMC degeneration is the pathological hallmark of CADASIL, leading to vessel wall thickening, luminal narrowing, reduced cerebral blood flow, and ischemic brain injury. Understanding VSMC pathology in CADASIL provides insights into vascular contributions to neurodegeneration and potential therapeutic targets.
graph TD
ANOTCH["3 Mutation"] --> B["Abnormal EGF-like Repeats"]
B --> C["NOTCH3 Accumulation"]
C --> D["GOM Deposition"]
D --> E["VSMC Degeneration"]
E --> F["Vessel Wall Thickening"]
F --> G["Luminal Narrowing"]
G --> H["Reduced CBF"]
H --> I["White Matter Injury"]
E --> J["BBB Dysfunction"]
J --> K["Neuroinflammation"]
I --> L["Vascular Dementia"]
K --> L
¶ CADASIL Genetics and Pathophysiology
| Feature |
Details |
| Location |
Chromosome 19p13.12 |
| Protein |
NOTCH3 receptor |
| Expression |
VSMCs, pericytes |
| Function |
Cell differentiation, survival |
| Mutations |
Cysteine-altering in EGF-like domains |
CADASIL-causing mutations are stereotypic:
- Cysteine gain/loss: Odd number of cysteines in EGF-like domain
- Hotspots: Exons 2-24 encoding EGF-like repeats
- Effect: Abnormal protein folding and aggregation
- Inheritance: Autosomal dominant with variable penetrance
- Extracellular domain: 34 EGF-like repeats
- Transmembrane domain: Single-pass
- Intracellular domain: Transcriptional activation
- Ligands: Jagged1/2, Delta-like 1/3/4
The characteristic pathological finding in CADASIL:
| Feature |
Description |
| Location |
VSMC basal membrane |
| Composition |
NOTCH3 ectodomain, TIMP3, vitronectin |
| Detection |
Electron microscopy (gold standard) |
| Specificity |
Pathognomonic for CADASIL |
graph LR
ANOTCH["3 Mutation"] --> B["Abnormal Folding"]
B --> C["Ectodomain Accumulation"]
C --> D["Protein Aggregation"]
D --> E["GOM Formation"]
E --> F["Adjacent VSMC Damage"]
F --> G["VSMC Degeneration"]
Progressive VSMC loss through:
- Protein aggregation stress: NOTCH3/GOM toxicity
- ER stress: Unfolded protein response activation
- Oxidative stress: Mitochondrial dysfunction
- Apoptosis: Programmed cell death pathways
- Impaired autophagy: Failed protein clearance
| Vessel Type |
Pathological Change |
| Small arteries |
Wall thickening, VSMC loss |
| Arterioles |
Fibrosis, hyalinosis |
| Capillaries |
Pericyte involvement |
| Veins |
Generally spared |
- Intimal hyperplasia: Fibrous intimal thickening
- Media degeneration: VSMC loss, collagen deposition
- Adventitial fibrosis: Perivascular collagen
- Luminal narrowing: 30-70% reduction common
| Region |
CBF Change |
Clinical Impact |
| White matter |
↓30-50% |
Cognitive decline |
| Basal ganglia |
↓20-40% |
Motor symptoms |
| Cortex |
↓10-30% |
Executive dysfunction |
| Hippocampus |
Variable |
Memory impairment |
| Feature |
Age of Onset |
Prevalence |
| Migraine with aura |
20-40 years |
40-60% |
| TIA/stroke |
40-60 years |
70-85% |
| Cognitive decline |
40-70 years |
60-80% |
| Psychiatric symptoms |
30-50 years |
30-50% |
| Gait disturbance |
50-70 years |
40-60% |
Characteristic neuroimaging features:
- White matter hyperintensities: Anterior temporal, external capsule
- Lacunar infarcts: Basal ganglia, thalamus, brainstem
- Cerebral microbleeds: 10-30% of patients
- Brain atrophy: Frontal, temporal predominance
graph TD
A["Young Adulthood"] --> B["Migraine with Aura"]
B --> C30s-40s: W["MH Accumulation"]
C --> D40s-50s: L["acunar Strokes"]
D --> E50s-60s: C["ognitive Decline"]
E --> F60s-70s: D["ementia"]
F --> G70s+: S["evere Disability"]
| Normal Function |
CADASIL Effect |
| VSMC differentiation |
Impaired |
| Cell survival signaling |
Reduced |
| Smooth muscle gene expression |
Decreased |
| Calcium handling |
Abnormal |
- NOTCH3 ectodomain accumulation: Progressive deposition
- TIMP3 recruitment: Matrix metalloproteinase inhibition
- Vitronectin binding: ECM remodeling disruption
- Clusterin aggregation: Chaperone system overload
| Mechanism |
Evidence |
Therapeutic Target |
| Oxidative stress |
↑ ROS markers |
Antioxidants |
| Inflammation |
↑ Cytokines |
Anti-inflammatory |
| BBB breakdown |
Albumin leakage |
Barrier protection |
| Impaired autophagy |
LC3 accumulation |
Autophagy enhancers |
CADASIL provides a model for understanding vascular contributions to neurodegeneration:
| Shared Feature |
CADASIL |
Sporadic VCI |
AD |
| VSMC loss |
Prominent |
Variable |
Present |
| White matter injury |
Severe |
Moderate |
Mild |
| BBB dysfunction |
Early |
Variable |
Late |
| Cognitive pattern |
Subcortical |
Mixed |
Cortical |
- Amyloid deposition: Increased in CADASIL vessels
- Tau pathology: Secondary to ischemic injury
- ApoE4 association: May accelerate decline
- Mixed dementia: CADASIL + AD pathology common
| Disorder |
Gene |
Vessel Size |
VSMC Involvement |
| CADASIL |
NOTCH3 |
Small |
Severe |
| CARASIL |
HTRA1 |
Small |
Moderate |
| RVCL |
TREX1 |
Small |
Variable |
| Fabry disease |
GLA |
Small-medium |
Gb3 accumulation |
- NOTCH3 sequencing: Standard diagnostic test
- Targeted exons: Exons 2-24 cover 95%+ mutations
- Variants of unknown significance: Clinical correlation needed
| Feature |
Sensitivity |
Specificity |
| GOM on EM |
45-90% |
~100% |
| NOTCH3 IHC |
85-95% |
~95% |
| Combined |
95%+ |
~100% |
| Biomarker |
Utility |
| Neurofilament light (NfL) |
Disease activity |
| MMP-9 |
Vessel wall turnover |
| TIMP3 |
GOM-related |
| Cystatin C |
Renal + vascular |
| Intervention |
Target |
Evidence |
| Antiplatelet therapy |
Stroke prevention |
Standard care |
| Blood pressure control |
Vascular protection |
Consensus |
| Statins |
Mixed evidence |
Inconsistent |
| Smoking cessation |
Risk reduction |
Essential |
| Approach |
Mechanism |
Status |
| NOTCH3 monoclonal antibodies |
Clear aggregates |
Preclinical |
| Autophagy enhancers |
Protein clearance |
Research |
| Anti-aggregation compounds |
Prevent GOM |
Preclinical |
| Gene therapy |
Correct mutation |
Research |
- Migraine: Standard prophylaxis (avoid vasoconstrictors)
- Depression: SSRIs, psychotherapy
- Cognitive symptoms: Cholinesterase inhibitors (limited benefit)
- Gait disorder: Physical therapy
- ESCAPE-CADASIL: Evaluating strategies for vascular protection
- CADASIL-TCH: Tadalafil for cerebral blood flow
- Anti-aggregation: Targeting GOM formation
graph TD
A["Therapeutic Targets"] --> B["Primary Prevention"]
A --> C["Disease Modification"]
A --> D["Symptom Management"]
B --> E["NOTCH3 Antibodies"]
B --> F["Gene Editing"]
C --> G["Autophagy Enhancement"]
C --> H["Anti-fibrotic Agents"]
D --> I["CBF Improvement"]
D --> J["Neuroprotection"]
- CSF biomarkers: NfL, tau, amyloid ratios
- Blood biomarkers: NfL, GFAP, inflammatory markers
- Imaging biomarkers: MRI, PET, ultrasound
- Functional biomarkers: CBF, vascular reactivity
| Assessment |
Frequency |
Purpose |
| Neurological exam |
Annual |
Disease progression |
| MRI brain |
Every 2-3 years |
Structural changes |
| Cognitive testing |
Annual |
Decline detection |
| Blood pressure |
Regular |
Risk management |
| Depression screening |
Annual |
Mental health |